Advances in diagnosing and managing antibody-mediated rejection

Pediatric Nephrology

Volumn 25, Issue 10, 2010, Pages 2035-2048

  Jordan, Stanley C ^a,d   Reinsmoen, Nancy ^b   Peng, Alice ^a   Lai, Chih Hung ^b   Cao, Kai ^b   Villicana, Rafael ^a   Toyoda, Mieko ^c   Kahwaji, Joseph ^a   Vo, Ashley A ^a  

^a Division of Gastroenterology and Hepatology   (United States)

^b HLA and Immunogenetics Laboratory   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antibody mediated rejection; Donor specific antibodies; IVIG; Rituximab

Indexed keywords

ANTIBODY; BORTEZOMIB; ECULIZUMAB; ENDOTHELIAL CELL ANTIBODY; HLA A ANTIGEN; HLA ANTIBODY; IMMUNOGLOBULIN; METHYLPREDNISOLONE SODIUM SUCCINATE; RITUXIMAB; THYMOCYTE ANTIBODY;

ANOREXIA; ANTIBODY DETECTION; ANTIBODY MEDIATED REJECTION; B LYMPHOCYTE; CELLULAR IMMUNITY; CHRONIC GRAFT REJECTION; COMPLEMENT SYSTEM; CONSTIPATION; DECREASED APPETITE; DESENSITIZATION; DIARRHEA; DRUG FEVER; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; GRAFT REJECTION; HUMAN; IMMUNOREGULATION; LOW DRUG DOSE; MALAISE; MENTAL DISEASE; NAUSEA; NEUTROPENIA; NONHUMAN; PERIPHERAL NEUROPATHY; PLASMA CELL; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SPLENECTOMY; THROMBOCYTOPENIA; VOMITING; WEAKNESS;

GRAFT REJECTION; HISTOCOMPATIBILITY; HLA ANTIGENS; HUMANS; KIDNEY TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 77956231885     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-009-1386-4     Document Type: Review

References (83)

1. RW Evans DL Manninen LP Garrison Jr LG Hart CR Blagg RA Gutman AR Hull EG Lowrie 1985 The quality of life of patients with end-stage renal disease N Engl J Med 312 553 559 10.1056/NEJM198502283120905 3918267
2. FK Port RA Wolfe EA Mauger DP Berling K Jiang 1993 Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients JAMA 270 1339 1343 10.1001/jama.270.11.1339 8360969
3. JD Russell ML Beecroft D Ludwin DN Churchill 1992 The quality of life in renal transplantation-a prospective study Transplantation 54 656 660 10.1097/00007890-199210000-00018 1412757
4. Organ Procurement Transplantation Network/Scientific Registry of Transplant Recipients: OPTN. (2009); http://www.optn.org/data/
5. United Network for Organ Sharing Data Base as of 5/30/2008. http://www.unos.org
6. SC Jordan D Tyan D Stablein M McIntosh S Rose A Vo M Toyoda C Davis R Shapiro D Adey D Milliner R Graff R Steiner G Ciancio S Sahney J Light 2004 Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial J Am Soc Nephrol 15 3256 3262 10.1097/01.ASN.0000145878.92906.9F 15579530
7. AA Vo M Lukovsky M Toyoda J Wang NL Reinsmoen CH Lai A Peng R Villicana SC Jordan 2008 Rituximab and intravenous immune globulin for desensitization during renal transplantation N Engl J Med 359 242 251 10.1056/NEJMoa0707894 18635429
8. RA Montgomery JE Locke KE King DL Segev DS Warren ES Kraus M Cooper CE Simpkins AL Singer ZA Stewart JK Melancon L Ratner AA Zachary M Haas 2009 ABO incompatible renal transplantation: a paradigm ready for broad implementation Transplantation 87 1246 1255 10.1097/TP.0b013e31819f2024 19384174
9. JM Gloor SR DeGoey AA Pineda SB Moore M Prieto SL Nyberg TS Larson MD Griffin SC Textor JA Velosa TR Schwab LA Fix MD Stegall 2003 Overcoming a positive crossmatch in living-donor kidney transplantation Am J Transplant 3 1017 1023 10.1034/j.1600-6143.2003.00180.x 12859539
10. Montgomery RA, Cooper M, Kraus E, Rabb H, Samaniego M, Simpkins CE, Sonnenday CJ, Ugarte RM, Warren DS, Zachary AA (2003) Renal transplantation at the Johns Hopkins Comprehensive Transplant Center. Clin Transpl: 199-213
11. SC Jordan MD Pescovitz 2006 Presensitization: the problem and its management Clin J Am Soc Nephrol 1 421 432 10.2215/CJN.01651105 17699241
12. D Glotz C Antoine P Julia B Pegaz-Fiornet A Duboust S Boudjeltia R Fraoui M Combes J Bariety 2004 Intravenous immunoglobulins and transplantation for patients with anti-HLA antibodies Transpl Int 17 1 8 10.1111/j.1432-2277.2004. tb00376.x 14685653
13. EJ Schweitzer JS Wilson M Fernandez-Vina M Fox M Gutierrez A Wiland J Hunter A Farney B Philosophe J Colonna BE Jarrell ST Bartlett 2000 A high panel-reactive antibody rescue protocol for cross-match-positive live donor kidney transplants Transplantation 70 1531 1536 10.1097/00007890-200011270-00023 11118102
14. SC Jordan AA Vo D Tyan CC Nast M Toyoda 2005 Current approaches to treatment of antibody-mediated rejection Pediatr Transplant 9 408 415 10.1111/j.1399-3046.2005.00363.x 15910400
15. K Solez RB Colvin LC Racusen M Haas B Sis M Mengel PF Halloran W Baldwin G Banfi AB Collins F Cosio DS David C Drachenberg G Einecke AB Fogo IW Gibson D Glotz SS Iskandar E Kraus E Lerut RB Mannon M Mihatsch BJ Nankivell V Nickeleit JC Papadimitriou P Randhawa H Regele K Renaudin I Roberts D Seron RN Smith M Valente 2008 Banff 07 classification of renal allograft pathology: updates and future directions Am J Transplant 8 753 760 10.1111/j.1600-6143.2008.02159.x 18294345
16. MJ Everly JJ Everly LJ Arend P Brailey B Susskind A Govil A Rike P Roy-Chaudhury G Mogilishetty RR Alloway A Tevar ES Woodle 2009 Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss Am J Transplant 9 1063 1071 10.1111/j.1600-6143.2009.02577.x 19344434
17. N Singh J Pirsch M Samaniego 2009 Antibody-mediated rejection: treatment alternatives and outcomes Transplant Rev (Orlando) 23 34 46
18. C Lefaucheur C Suberbielle-Boissel GS Hill D Nochy J Andrade C Antoine C Gautreau D Charron D Glotz 2008 Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation Am J Transplant 8 324 331 10.1111/j.1600-6143.2008.02342.x 18162086
19. NL Reinsmoen CH Lai A Vo K Cao G Ong M Naim Q Wang SC Jordan 2008 Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy Transplantation 86 820 825 10.1097/TP.0b013e3181856f98 18813107
20. RA Bray PW Nickerson RH Kerman HM Gebel 2004 Evolution of HLA antibody detection: technology emulating biology Immunol Res 29 41 54 10.1385/IR:29:1-3:041 15181269
21. JC Scornik W Clapp PR Patton WJ Van der Werf AW Hemming AI Reed RJ Howard 2001 Outcome of kidney transplants in patients known to be flow cytometry crossmatch positive Transplantation 71 1098 1102 10.1097/00007890-200104270- 00015 11374409
22. R Wen V Wu S Dmitrienko A Yu R Balshaw PA Keown 2006 Biomarkers in transplantation: Prospective, blinded measurement of predictive value for the flow cytometry crossmatch after negative antiglobulin crossmatch in kidney transplantation Kidney Int 70 1474 1481 10.1038/sj.ki.5001785 16941026
23. ER Vasilescu EK Ho AI Colovai G Vlad A Foca-Rodi GS Markowitz V D'Agati MA Hardy LE Ratner N Suciu-Foca 2006 Alloantibodies and the outcome of cadaver kidney allografts Hum Immunol 67 597 604 10.1016/j.humimm.2006.04.012 16916655
24. AA Zachary RA Montgomery MS Leffell 2005 Factors associated with and predictive of persistence of donor-specific antibody after treatment with plasmapheresis and intravenous immunoglobulin Hum Immunol 66 364 370 10.1016/j.humimm.2005.01.032 15866699
25. R Fredrich M Toyoda LS Czer K Galfayan O Galera A Trento D Freimark S Young SC Jordan 1999 The clinical significance of antibodies to human vascular endothelial cells after cardiac transplantation Transplantation 67 385 391 10.1097/00007890-199902150-00008 10030283
26. M Toyoda A Petrosian SC Jordan 1999 Immunological characterization of anti-endothelial cell antibodies induced by cytomegalovirus infection Transplantation 68 1311 1318 10.1097/00007890-199911150-00016 10573069
27. D Dragun B Hegner 2009 Non-HLA antibodies post-transplantation: clinical relevance and treatment in solid organ transplantation Contrib Nephrol 162 129 139 10.1159/000170845 19001820
28. ME Breimer L Rydberg AM Jackson DP Lucas AA Zachary JK Melancon J Von Visger R Pelletier SL Saidman WW Williams Jr J Holgersson G Tyden GK Klintmalm S Coultrup S Sumitran-Holgersson P Grufman 2009 Multicenter evaluation of a novel endothelial cell crossmatch test in kidney transplantation Transplantation 87 549 556 10.1097/TP.0b013e3181949d4e 19307793
29. B Grandtnerova N Mackova B Hovoricova E Jahnova 2008 Hyperacute rejection of living related kidney grafts caused by endothelial cell-specific antibodies: case reports Transplant Proc 40 2422 2424 10.1016/j.transproceed.2008.06.014 18790254
30. P Stastny Y Zou Y Fan Z Qin B Lavingia 2009 The emerging issue of MICA antibodies: antibodies to MICA and other antigens of endothelial cells Contrib Nephrol 162 99 106 10.1159/000170842 19001817
31. Y Zou P Stastny C Susal B Dohler G Opelz 2007 Antibodies against MICA antigens and kidney-transplant rejection N Engl J Med 357 1293 1300 10.1056/NEJMoa067160 17898098
32. SC Jordan M Toyoda AA Vo 2009 Intravenous immunoglobulin a natural regulator of immunity and inflammation Transplantation 88 1 6 10.1097/TP.0b013e3181a9e89a 19584672
33. F Nimmerjahn JV Ravetch 2008 Anti-inflammatory actions of intravenous immunoglobulin Annu Rev Immunol 26 513 533 10.1146/annurev.immunol.26.021607. 090232 18370923
34. T Tha-In J Bayry HJ Metselaar SV Kaveri J Kwekkeboom 2008 Modulation of the cellular immune system by intravenous immunoglobulin Trends Immunol 29 608 615 10.1016/j.it.2008.08.004 18926775
35. R Clynes 2007 Protective mechanisms of IVIG Curr Opin Immunol 19 646 651 10.1016/j.coi.2007.09.004 18032008
36. SV Kaveri S Lacroix-Desmazes J Bayry 2008 The antiinflammatory IgG N Engl J Med 359 307 309 10.1056/NEJMcibr0803649 18635437
37. TV Arumugam SC Tang JD Lathia A Cheng MR Mughal S Chigurupati T Magnus SL Chan DG Jo X Ouyang DP Fairlie DN Granger A Vortmeyer M Basta MP Mattson 2007 Intravenous immunoglobulin (IVIG) protects the brain against experimental stroke by preventing complement-mediated neuronal cell death Proc Natl Acad Sci USA 104 14104 14109 10.1073/pnas.0700506104 17715065
38. TV Arumugam PK Selvaraj TM Woodruff MP Mattson 2008 Targeting ischemic brain injury with intravenous immunoglobulin Expert Opin Ther Targets 12 19 29 10.1517/14728222.12.1.19 18076367
39. M Basta F Van Goor S Luccioli EM Billings AO Vortmeyer L Baranyi J Szebeni CR Alving MC Carroll I Berkower SS Stojilkovic DD Metcalfe 2003 F(ab)'2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins Nat Med 9 431 438 10.1038/nm836 12612546
40. TV Arumugam TM Woodruff JD Lathia PK Selvaraj MP Mattson SM Taylor 2009 Neuroprotection in stroke by complement inhibition and immunoglobulin therapy Neuroscience 158 1074 1089 10.1016/j.neuroscience.2008.07.015 18691639
41. M Basta 2008 Ambivalent effect of immunoglobulins on the complement system: activation versus inhibition Mol Immunol 45 4073 4079 10.1016/j.molimm.2008.07.012 18706699
42. JM Thurman 2007 Triggers of inflammation after renal ischemia/reperfusion Clin Immunol 123 7 13 10.1016/j.clim.2006.09.008 17064966
43. A Sameulsson TL Towers JV Ravetch 2001 Anti-inflamatory activity of IVIG mediated through the inhibitory Fc receptor Science 29 484 6 10.1126/science.291.5503.484
44. Y Kaneko F Nimmerjahn MP Madaio JV Ravetch 2006 Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors J Exp Med 203 789 797 10.1084/jem.20051900 16520389
45. RM Anthony F Nimmerjahn DJ Ashline VN Reinhold JC Paulson JV Ravetch 2008 Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc Science 320 373 376 10.1126/science.1154315 18420934
46. Y Kaneko F Nimmerjahn JV Ravetch 2006 Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation Science 313 670 673 10.1126/science.1129594 16888140
47. RM Anthony F Wermeling MC Karlsson JV Ravetch 2008 Identification of a receptor required for the anti-inflammatory activity of IVIG Proc Natl Acad Sci USA 105 19571 19578 10.1073/pnas.0810163105 19036920
48. SC Jordan AW Quartel LS Czer D Admon G Chen MC Fishbein J Schwieger RW Steiner C Davis DB Tyan 1998 Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action Transplantation 66 800 805 10.1097/00007890-199809270-00017 9771846
49. DH Casadei CRM del G Opelz JC Golberg JA Argento G Greco OE Guardia E Haas EH Raimondi 2001 A randomized and prospective study comparing treatment with high-dose intravenous immunoglobulin with monoclonal antibodies for rescue of kidney grafts with steroid-resistant rejection Transplantation 71 53 58 10.1097/00007890-200101150-00009 11211195
50. PP Luke VP Scantlebury ML Jordan CA Vivas TR Hakala A Jain A Somani S Fedorek P Randhawa R Shapiro 2001 Reversal of steroid- and anti-lymphocyte antibody-resistant rejection using intravenous immunoglobulin (IVIG) in renal transplant recipients Transplantation 72 419 422 10.1097/00007890-200108150- 00010 11502969
51. C Lefaucheur D Nochy J Andrade J Verine C Gautreau D Charron GS Hill D Glotz C Suberbielle-Boissel 2009 Comparison of combination Plasmapheresis/IVIg/ anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection Am J Transplant 9 1099 1107 10.1111/j.1600-6143.2009.02591.x 19422335
52. ME Reff K Carner KS Chambers PC Chinn JE Leonard R Raab RA Newman N Hanna DR Anderson 1994 Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20 Blood 83 435 445 7506951
53. JC Edwards L Szczepanski J Szechinski A Filipowicz-Sosnowska P Emery DR Close RM Stevens T Shaw 2004 Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis N Engl J Med 350 2572 2581 10.1056/NEJMoa032534 15201414
54. AD Salama CD Pusey 2006 Drug insight: rituximab in renal disease and transplantation Nat Clin Pract Nephrol 2 221 230 10.1038/ncpneph0133 16932428
55. JC Edwards G Cambridge 2006 B-cell targeting in rheumatoid arthritis and other autoimmune diseases Nat Rev Immunol 6 394 403 10.1038/nri1838 16622478
56. R Stasi N Cooper G Del Poeta E Stipa M Laura Evangelista E Abruzzese S Amadori 2008 Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab Blood 112 1147 1150 10.1182/blood-2007-12-129262 18375792
57. SN Liossis PP Sfikakis 2008 Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells Clin Immunol 127 280 285 10.1016/j.clim.2008.01.011 18337174
58. H Genberg A Hansson A Wernerson L Wennberg G Tyden 2007 Pharmacodynamics of rituximab in kidney transplantation Transplantation 84 S33 36 10.1097/01.tp.0000296122.19026.0f 18162986
59. EJ Ramos HS Pollinger MD Stegall JM Gloor A Dogan JP Grande 2007 The effect of desensitization protocols on human splenic B-cell populations in vivo Am J Transplant 7 402 407 10.1111/j.1600-6143.2006.01632.x 17241113
60. JH Anolik J Barnard T Owen B Zheng S Kemshetti RJ Looney I Sanz 2007 Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy Arthritis Rheum 56 3044 3056 10.1002/art.22810 17763423
61. MC Levesque EW St Clair 2008 B cell-directed therapies for autoimmune disease and correlates of disease response and relapse J Allergy Clin Immunol 121 13 21 10.1016/j.jaci.2007.11.030 18206502 quiz 22-13
62. M Sarwal MS Chua N Kambham SC Hsieh T Satterwhite M Masek O Salvatierra Jr 2003 Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling N Engl J Med 349 125 138 10.1056/NEJMoa035588 12853585
63. V Zarkhin L Li N Kambham T Sigdel O Salvatierra MM Sarwal 2008 A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation Am J Transplant 8 2607 2617 10.1111/j.1600-6143.2008. 02411.x 18808404
64. OM Steinmetz F Lange-Husken JE Turner A Vernauer U Helmchen RA Stahl F Thaiss U Panzer 2007 Rituximab removes intrarenal B cell clusters in patients with renal vascular allograft rejection Transplantation 84 842 850 10.1097/01.tp.0000282786.58754.2b 17984836
65. YT Becker BN Becker JD Pirsch HW Sollinger 2004 Rituximab as treatment for refractory kidney transplant rejection Am J Transplant 4 996 1001 10.1111/j.1600-6143.2004.00454.x 15147435
66. Z Kaposztas H Podder S Mauiyyedi O Illoh R Kerman M Reyes V Pollard BD Kahan 2009 Impact of rituximab therapy for treatment of acute humoral rejection Clin Transplant 23 63 73 10.1111/j.1399-0012.2008.00902.x 19200217
67. S Faguer N Kamar C Guilbeaud-Frugier M Fort A Modesto A Mari D Ribes O Cointault L Lavayssiere J Guitard D Durand L Rostaing 2007 Rituximab therapy for acute humoral rejection after kidney transplantation Transplantation 83 1277 1280 10.1097/01.tp.0000261113.30757.d1 17496547
68. A Celik F Saglam C Cavdar A Sifil K Atila S Sarioglu S Bora H Gulay T Camsari 2008 Successful therapy with rituximab of refractory acute humoral renal transplant rejection: a case report Transplant Proc 40 302 304 10.1016/j.transproceed.2007.11.011 18261611
69. WR Mulley FJ Hudson BD Tait AM Skene JP Dowling PG Kerr J Kanellis 2009 A single low-fixed dose of rituximab to salvage renal transplants from refractory antibody-mediated rejection Transplantation 87 286 289 10.1097/TP. 0b013e31819389cc 19155986
70. GT Moscoso-Solorzano JM Baltar M Seco C Lopez-Larrea G Mastroianni-Kirsztajn F Ortega 2007 Single dose of Rituximab plus plasmapheresis in an HIV patient with acute humoral kidney transplant rejection: a case report Transplant Proc 39 3460 3462 10.1016/j.transproceed.2007.09.043 18089407
71. Wade E, Goral S, Kearns J, Pierce E, Trofe J, Bloom R, Kamoun M (2006) Experience with antibody-mediated rejection in kidney allograft recipients. Clin Transpl:439-446
72. YW Yang WC Lin MS Wu PH Lee MK Tsai 2008 Early diagnosis and successful treatment of acute antibody-mediated rejection of a renal transplant Exp Clin Transplant 6 211 214 18954299
73. A Vo K Cao C-H Lai N Reinsmoen M Toyoda S Ge A Peng R Villicana SC Jordan 2009 Characteristics of patients who develop antibody-mediated rejection (AMR) post-transplant after desensitization with IVIG + rituximab: analysis of risk factors and outcomes, (Abstract #494) Am J Transplantation 9 334
74. C Liu H Noorchashm JA Sutter M Naji EL Prak J Boyer T Green MR Rickels JE Tomaszewski B Koeberlein Z Wang ME Paessler E Velidedeoglu SY Rostami M Yu CF Barker A Naji 2007 B lymphocyte-directed immunotherapy promotes long-term islet allograft survival in nonhuman primates Nat Med 13 1295 1298 10.1038/nm1673 17965721
75. L Kessler A Parissiadis F Bayle F Moreau M Pinget N Froelich JP Cazenave T Berney PY Benhamou D Hanau 2009 Evidence for humoral rejection of a pancreatic islet graft and rescue with rituximab and IV immunoglobulin therapy Am J Transplant 9 1961 1966 10.1111/j.1600-6143.2009.02711.x 19522877
76. H Billing S Rieger J Ovens C Susal A Melk R Waldherr G Opelz B Tonshoff 2008 Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients Transplantation 86 1214 1221 10.1097/TP.0b013e3181880b35 19005402
77. T Fehr B Rusi A Fischer H Hopfer RP Wuthrich A Gaspert 2009 Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection Transplantation 87 1837 1841 10.1097/TP.0b013e3181a6bac5 19543061
78. MP Curran K McKeage 2009 Bortezomib: a review of its use in patients with multiple myeloma Drugs 69 859 888 10.2165/00003495-200969070-00006 19441872
79. HL Trivedi PI Terasaki A Feroz MJ Everly AV Vanikar V Shankar VB Trivedi H Kaneku AK Idica PR Modi SI Khemchandani SD Dave 2009 Abrogation of anti-HLA antibodies via proteasome inhibition Transplantation 87 1555 1561 10.1097/TP.0b013e3181a4b91b 19461494
80. MJ Everly JJ Everly B Susskind P Brailey LJ Arend RR Alloway P Roy-Chaudhury A Govil G Mogilishetty AH Rike M Cardi G Wadih A Tevar ES Woodle 2008 Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection Transplantation 86 1754 1761 10.1097/TP.0b013e318190af83 19104417
81. C Parker 2009 Eculizumab for paroxysmal nocturnal haemoglobinuria Lancet 373 759 767 10.1016/S0140-6736(09)60001-5 19144399
82. JM Williams ZE Holzknecht TB Plummer SS Lin GJ Brunn JL Platt 2004 Acute vascular rejection and accommodation: divergent outcomes of the humoral response to organ transplantation Transplantation 78 1471 1478 10.1097/01.TP.0000140770. 81537.64 15599311
83. M Stegall T Diwan J Burns P Dean 2009 Prevention of acute humoral rejection with C5 inhibition, (Abstract #174) Am J Transplantation 9 241